ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma

M. L. Goldman1, K. Zhou2, J. L. Dodge1, F. Yao1, N. Mehta1

1Department of Medicine, UCSF, San Francisco, CA, 2Department of Medicine, USC, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: B-138

Keywords: Hepatocellular carcinoma, Liver transplantation, Mortality, Tumor recurrence

Session Information

Session Name: Poster Session B: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to <500 ng/mL with local-regional therapy (LRT) before liver transplant (LT). We hypothesized that both of these AFP thresholds should be lowered to further improve LT outcome. We therefore aimed to evaluate the effects of AFP reduction on post-LT HCC outcomes among HCC patients with initial AFP >100 but <1,000 ng/mL.

*Methods: We identified 1766 HCC patients in the UNOS registry who underwent LT from 01/2005 to 09/2015 with initial AFP of 100 to 999 ng/mL at listing with MELD exception. Patients were grouped by AFP within 3 months of LT of <100, 100-499, and ≥500 ng/mL. Survival was compared using the Kaplan-Meier method. Factors associated with post-LT survival and HCC recurrence were assessed in a multivariable Cox regression model.

*Results: Among 1766 included patients, the initial AFP was 100-499 in 1458 (83%) and 500-999 in 308 (17%) patients. For 887 patients (50%) this was the only AFP value recorded while on the LT waitlist. In the remaining 879 patients, 436 (50%) had an AFP reduction to <100 at LT and 443 (50%) had an AFP ≥100 at LT, including 109 (12%) with AFP ≥500. LRT was reported in 91% of patients with AFP <100, 83% with AFP 100-499, and 69% with AFP ≥500 at LT (p<0.001). The median wait time was shortest in the group with only a single AFP and longest in the group with AFP <100 at LT (1 versus 7 months, p<0.001). The 5-year post-LT survival was 73% for AFP <100, 70% for AFP 100-499, and 56% for AFP ≥500 at LT (log-rank p=0.003). The probability of HCC recurrence at 5 years was 13%, 19%, and 24%, respectively (log-rank p=0.007). In multivariable analysis, AFP ≥500 at LT was associated with a greater risk of post-LT death (HR 1.4, 95% CI 1.1-1.9, p=0.02) and HCC recurrence (HR 1.6, 95% CI 1.0-2.4, p=0.05) when compared to AFP <100 at LT, after adjusting for donor risk index, age, race/ethnicity, Child’s class, and tumor diameter at LT.

*Conclusions: In HCC patients with initial AFP > 100 and <1,000 ng/mL at LT listing, those with AFP >500 ng/mL at LT had a 5-year post-LT survival of only 56%, versus 73% for those achieving AFP reduction to <100 ng/mL at LT. Our results suggest that the AFP threshold of >1000 ng/mL for exclusion from LT in the current UNOS policy may be lowered to >500 ng/mL, with a target AFP reduction to < 100 ng/mL, to further optimize post-LT outcomes.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-impact-of-initial-alpha-fetoprotein-100-but/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences